Navigation Links
Levels of hepatitis C virus higher among African-Americans and males
Date:7/10/2012

Epidemiologists have determined that levels of hepatitis C virus (HCV) found among injection drug users (IDUs) were higher in individuals who are male or African American even after differences in other factors were considered. The study, which was funded by the National Cancer Institute and performed with collaborators from the National Institutes of Health Clinical Center and the University of California - San Francisco, was the first to simultaneously examine the association of demographic, viral and human genetic factors on HCV RNA levels. Results of the study published in the July issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), also showed higher levels of HCV among IDUs who were co-infected with human immunodeficiency virus (HIV).

A 2010 report from the Centers for Disease Control and Prevention (CDC) estimates that up to 3.9 million Americans have chronic HCVa leading cause of liver cancer, end-stage liver disease and liver transplantation. According to the CDC 17,000 new cases and 2,800 acute cases of HCV were reported in 2010. Previous epidemiologic studies suggest one-third of those 18 to 30 year-old IDUs and up to 90% of older IDUs are infected with HCV.

"With such a high incidence and prevalence of hepatitis C virus infection among IDUs, it is important to understand the characteristics of the infection in this group," explains lead author Dr. Thomas O'Brien of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Rockville, MD. "The HCV RNA level is an important predictor of response to treatment in patients with chronic hepatitis C. Our study is the first to examine simultaneously the viral, demographic, and genetic factors that impact HCV levels in ethnically diverse IDUs."

Participants were originally recruited for the Urban Health Studya multi-ethnic group of IDUs in San Francisco. Researchers used interview data and biological samples from participants to analyze demographic, viral and host characteristics of cancer-causing viruses. A total of 1701 participants had detectable HCV RNA and were included in the present study. The median age at enrollment was 46 years and median age of first illicit drug injection was 18 years. Close to 75% of participants were men and 56% were African American, 34% European (non-Hispanic) and 7% Latino (non-African American).

Adjusted analysis revealed that age, gender, racial ancestry, HIV-1 infection, and IL28B rs12979860 genotype were all independently associated with the HCV RNA level. "We know that the level of HCV is an important predictor of treatment response and that these levels seem to be influenced by a number of demographic, clinical, viral and human genetic factors," concludes Dr. O'Brien.


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related biology news :

1. Seabirds study shows plastic pollution reaching surprising levels off coast of Pacific Northwest
2. Lab-on-a-chip detects trace levels of toxic vapors in homes near Utah Air Force Base
3. Low vitamin D levels linked to weight gain in some older women
4. New study: Snacking on raisins significantly reduces overall post-meal blood sugar levels
5. Increasing levels of carbon dioxide in Arctic coastal seas
6. UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women
7. Cardio fitness levels of breast cancer patients may affect survival
8. Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals
9. Research!America says house funding levels for FY13 could undermine medical progress
10. High levels of TRAIL protein in breast milk might contribute to anticancer activity
11. Growing nitrous oxide levels explained
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... ... August 25, 2020 , ... ... mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology ... VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate to severe ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to ... Roche and J&J have annual Research and Development spending in excess of US ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. (Nasdaq: ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ... strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech , ... Solutions, in a one hour live webinar on Thursday, August 13, 2020 ... for drugs and medical devices. Specifically, for medical devices, the NMPA has departments dealing ...
(Date:7/18/2020)... ... 17, 2020 , ... dicentra , a leading Contract ... industries, is pleased to announce that Charles Galea has joined its clinical trials ... is an accomplished and results-driven sales executive with over 10 years of expertise ...
Breaking Biology Technology: